Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Oracle faces downside risk with $100B debt, tripled leases, halted buybacks, equity issuance, and elevated valuation versus ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

With a new year swiftly coming, Steve Miranda, Executive Vice President, Applications Development at Oracle, recently joined the CRM Playaz to discuss what the year ahead has in store in the ...

Oracle (ORCL) is rated 'Buy' due to a major valuation dislocation versus its $523B RPO backlog, despite recent CapEx-driven ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Oracle led tech stocks lower Thursday after the cloud computing provider's quarterly sales missed analysts' estimates.

Access to Oracle Red Bull Racing’s garage in Abu Dhabi, the final race of the season, reveals how Monte Carlo simulations, artificial intelligence and Oracle Cloud Infrastructure power split-second ...

It hasn't been that long since Oracle was an AI darling. A lot can change in a few months.

Amazon Q Developer is a useful AI-powered coding assistant with chat, CLI, Model Context Protocol and agent support, and AWS ...